These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18272105)

  • 1. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
    Boden WE; Hoekstra J; Miller CD
    Am J Emerg Med; 2008 Feb; 26(2):212-20. PubMed ID: 18272105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
    Radke PW; Schunkert H
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
    [No Abstract]   [Full Text] [Related]  

  • 3. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
    [No Abstract]   [Full Text] [Related]  

  • 5. [New antiaggregants and their importance for the practitioner].
    Tsakiris DA
    Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 13. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiplatelet agents.
    White HD; French JK; Ellis CJ
    Aust N Z J Med; 1998 Aug; 28(4):558-64. PubMed ID: 9777140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
    Ben-Yehuda O
    J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
    Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
    Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
    Koziński M; Bielis L; Wiśniewska-Szmyt J; Sukiennik A; Grabczewska Z; Swiatkiewicz I; Ziołkowski M; Rość D; Kubica J
    Cardiol J; 2008; 15(6):530-6. PubMed ID: 19039757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.